Katsi Vasiliki, Georgountzos Georgios, Kallistratos Manolis S, Zerdes Ioannis, Makris Thomas, Manolis Athanasios J, Nihoyannopoulos Petros, Tousoulis Dimitris
Department of Cardiology, Hippokration HospitalAthens, Greece.
School of Medicine, University of PatrasPatras, Greece.
Front Pharmacol. 2017 May 5;8:247. doi: 10.3389/fphar.2017.00247. eCollection 2017.
Preeclampsia has been linked to high morbidity and mortality during pregnancy. However, no efficient pharmacological options for the prevention of this condition are currently available. Preeclampsia is thought to share several pathophysiologic mechanisms with cardiovascular disease, which has led to investigations for the potential role of statins (HMG CoA reductase inhibitors) in its prevention and early management. Pravastatin seems to have a safer pharmacokinetic profile compared to other statins, however, the existing preclinical evidence for its effectiveness in preeclampsia treatment has been mostly restricted to animal models. This review aims to summarize the current data and delineate the potential future role of statins in the prevention and management of preeclampsia.
子痫前期与妊娠期的高发病率和死亡率相关。然而，目前尚无有效的预防该疾病的药物选择。子痫前期被认为与心血管疾病有若干共同的病理生理机制，这促使人们研究他汀类药物（HMG CoA还原酶抑制剂）在其预防和早期管理中的潜在作用。与其他他汀类药物相比，普伐他汀似乎具有更安全的药代动力学特征，然而，其在子痫前期治疗中有效性的现有临床前证据大多局限于动物模型。本综述旨在总结当前数据，并阐述他汀类药物在子痫前期预防和管理中的潜在未来作用。
